Research focus: novel approach to advance treatment of KRAS-driven non-small cell lung cancer based on ERK5 and FAK inhibition
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Research focus: novel approach to advance treatment of KRAS-driven non-small cell lung cancer based on ERK5 and FAK inhibition
-
ナレーター：
-
著者：
このコンテンツについて
We speak with Dr. Georgia Konstantinidou and Dr. Chiara Pozzato from University of Bern about their recent pre-clinical research investigating a new potential treatment approach for KRAS driven cancers. The conversation explores the role of FAK signalling in KRAS driven NSCLC and potential approaches to bypass drug resistance against FAK inhibitors from the molecular mechanisms involved to the impact of their study for the wider cancer research community.
This study has been published in EMBO Molecular Medicine and was included in the EACR's Highlights in Cancer Research, a summary of the most interesting and impactful recent papers in cancer research.
🔗 Read more about the publication: https://magazine.eacr.org/highlights-in-cancer-research-december-2024/7/
🔗 Access transcripts for all our episodes at magazine.eacr.org/podcast